Apellis Pharmaceuticals

Subsidiary of Biogen (BIIB)

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Pegcetacoplan(Empaveli)
Approved
Complement C3Peptide
Complement-Mediated Renal DiseaseParoxysmal Nocturnal Hemoglobinuria

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
Pegcetacoplan · EmpaveliPhase 3C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G) …
Est. primary completion 2027-07 · NCT05809531 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Pegcetacoplan · EmpaveliPhase 2Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
Est. primary completion 2028-12 · NCT04901936 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Pegcetacoplan · EmpaveliPhase 3C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) …
Est. primary completion 2031-01-17 · NCT07898774 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.